News

TIAP Voices: Providing Critical Resources to Realize the Opportunity Before Us By: Prakash Gowd, TIAP Vice President Having recently joined TIAP as Vice President, I wanted to connect with our…

TIAP Features: Fibrocor Therapeutics — Getting to the Core of Fibrosis From its foundational world-class research, its attraction of global investment and global talent to its impending advancement of multiple…

Fibrocor Therapeutics enters into research and development collaboration with McQuade Center for Strategic Research and Development to advance Alport Syndrome program Agreement includes a single digit million US$ upfront payment…

TIAP FEATURES: Vasomune Therapeutics – Tackling Vascular Dysfunction and Boosting Host Defenses From viral and bacterial pneumonia and sepsis, to acute kidney injury, hemorrhagic shock, stroke, and complications associated with…

As part of Ontario’s Critical Technologies initiative, TIAP is pleased to be partnering with OBIO® to offer new support to accelerate the health science industry’s use of cutting-edge technologies. OBIO’s…

TIAP, University of Toronto, and Vector Institute Enter into New Collaboration Organizations bring together their DaRMoD and UTEST programs to help advance six emerging Ontario ventures Toronto Innovation Acceleration Partners…

TIAP Strengthens Leadership Team with Appointment of Prakash Gowd as Vice President Toronto Innovation Acceleration Partners (TIAP) is pleased to announce the appointment of Prakash Gowd MBA, BSc Pharm, C.Dir…

Radiant to Assess Multi-Valent, Multi-Specific Multabodies as Potential Treatments for HIV Gates Foundation funding for an approach that leverages Radiant’s breakthrough Multabody™ platform TORONTO--(BUSINESS WIRE)--Radiant Biotherapeutics, a startup biotechnology company…

TIAP FEATURES: Zucara Therapeutics – Building on Canada’s Rich Research History to Dramatically Change Diabetes Disease Management “I think people know quite a bit about high blood sugar and the…

Phenomic Enters into Strategic Research Collaboration with Astellas for Solid Tumor Cell Therapies November 30, 2023 08:00 AM Eastern Standard Time   TORONTO & WALTHAM, Mass.--(BUSINESS WIRE)--Phenomic AI Inc. (“Phenomic”), a…